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ABSTRACT
Genomic complexity identified by chromosome banding analysis (CBA) predicts a 
worse clinical outcome in CLL patients treated either with standard or new treatments. 
Herein, we analyzed the clinical impact of complex karyotypes (CK) with or without 
high-risk FISH deletions (ATM and/or TP53, HR-FISH) in a cohort of 1045 untreated 
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INTRODUCTION
Well-established poor prognostic factors in chronic 
lymphocytic leukemia (CLL) include deletions in 11q, 
which involve ATM locus (delATM), and losses affecting 
TP53 gene located in 17p13 (delTP53) detected by 
fluorescence in situ hybridization (FISH) [1]. While 
the adverse prognosis of delATM has been partially 
overcome by chemoimmunotherapy-based treatments, 
patients showing TP53 deletions or mutations are 
typically resistant to these treatments [2, 3]. New agents 
acting independently of the p53 pathway have changed 
the treatment response rate for CLL patients with TP53 
abnormalities [4, 5]. However, recent studies have 
revealed that current FISH analyses (using Dohner’s 
hierarchical model probes) underestimate the true genomic 
complexity revealed by chromosome banding analysis 
(CBA) which predicts a worse clinical outcome in patients 
treated either with standard treatments or new agents [6-
11]. The aims of the present study were: (i) to describe 
and compare the characteristics and clinical course of 
CLL patients according to karyotype complexity detected 
by CBA, (ii) to analyze the impact of complex karyotype 
(CK) and high-risk FISH deletions (ATM and/or TP53, 
HR-FISH) on time to the first therapy and overall survival. 
RESULTS AND DISCUSSION
In the whole series, 435/1043 (41.6%) patients 
displayed abnormal karyotypes, being 99 (9.5%) complex. 
While most patients with abnormal but non-CK carried a 
single aberration (267/336, 80%), cases with CK displayed 
a median of 4 abnormalities (range: 3-18). Of note, 
structural aberrations were slightly predominant in both 
groups (63% and 57% in CK and non-CK, respectively). 
Notably, abnormal karyotypes from non-CK were 
mainly restricted to known recurrent CLL aberrations, 
namely trisomy 12 (37%), 13q14 structural anomalies 
(17% deletions and 4% translocations), del(11q) (12%), 
and translocations involving 14q (6%). On the contrary, 
CK patients displayed a wide variety of abnormalities 
distributed along the genome, which reflected the genomic 
instability of this group. Among them, the most frequent 
were 17p structural rearrangements (deletions, unbalanced 
translocations or isochromosome 17q) leading to TP53 
loss (26%), trisomy 12 (26%), del(13q) (19%), del(11q) 
(16%), trisomy 18 (11%) and del(6q) (10%). In addition, 
clonal evolution by CBA was identified in 33/99 (33%) 
patients with CK. Detailed karyotypes from those patients 
from CK group are displayed in Supplementary Table 3.
The CK group included patients with more advanced 
disease at diagnosis, including a higher proportion of 
patients diagnosed at Binet stage B/C (22% vs 11%; 
P = 0.001) and higher β2-microglobulin levels (2.6 mg/L 
vs 2 mg/L; P < 0.001). Moreover, features of aggressive 
disease were also observed: higher CD38 (33% vs 20%; 
P = 0.007) and ZAP-70 (46% vs 30%; P = 0.018) positivity 
rates, delATM (25% vs 7%; P < 0.001) and delTP53 
(40% vs 5%; P < 0.001). Despite the limited availability 
of IGHV data in this retrospective cohort (N = 98/1045), 
CK group also displayed a significant higher proportion 
of unmutated IGHV genes [71% (15/21) vs 23% (18/77); 
P < 0.001]. Indeed, CK group showed a significant higher 
two-year cumulative incidence of treatment (48%, 95%CI 
36-58%) than non-CK (20%, 95%CI 18-23%; P < 0.001), 
as well as a shorter overall survival (OS) (79 mo vs not 
reached; P < 0.001). The delTP53 enrichment observed 
in CK group was in accordance with the previously 
described frequencies (ranging from 28-50%) and 
could be underlying genomic instability leading to CK 
[6, 9, 12–13]. However, only 44.4% (40/90) patients with 
delTP53 showed a CK. CK negatively impacted on OS 
even within delTP53 cases (38 mo vs 133 mo; P < 0.001). 
In this regard, when patients were categorized regarding 
both CK and HR-FISH, no relevant differences in clinical 
characteristics at diagnosis were observed among those 
patients with at least one high-risk cytogenetic marker 
(CK and/or HR-FISH) (Table 1). Nevertheless, patients 
could be stratified in terms of time to first treatment 
(Figure 1). Of note, while patients with both HR-FISH and 
CK showed the worst median OS (52 mo) being clearly 
distinct from those non-CK and non-HR-FISH (median not 
MBL/CLL patients. In all, 99/1045 (9.5%) patients displayed a CK. Despite ATM and 
TP53 deletions were more common in CK (25% vs 7%; P < 0.001; 40% vs 5%; P < 
0.001, respectively), only 44% (40/90) patients with TP53 deletions showed a CK. CK 
group showed a significant higher two-year cumulative incidence of treatment (48% 
vs 20%; P < 0.001), as well as a shorter overall survival (OS) (79 mo vs not reached; 
P < 0.001). When patients were categorized regarding CK and HR-FISH, those with 
both characteristics showed the worst median OS (52 mo) being clearly distinct from 
those non-CK and non-HR-FISH (median not reached), but no significant differences 
were detected between cases with only CK or HR-FISH. Both CK and TP53 deletion 
remained statistically significant in the multivariate analysis for OS. In conclusion, 
CK group is globally associated with advanced disease and poor prognostic markers. 
Further investigation in larger cohorts with CK lacking HR-FISH is needed to elucidate 
which mechanisms underlie the poor outcome of this subgroup.
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reached), no significant differences were detected between 
cases with only CK or HR-FISH (Figure 1). Similarly, if 
only CK and delTP53 were considered, no differences 
in OS for CK patients lacking delTP53 and those with 
delTP53 but non-CK were observed (132 mo vs 89 mo; 
P = 0.269). In the multivariate analysis for OS, both CK 
and delTP53 remained statistically significant. Of note, 
delTP53 was the predictor showing higher hazard ratio in 
the multivariate analysis (Table 2). Unfortunately, as this 
is a retrospective and multicentric study, TP53 mutational 
status was not routinely assessed and availability of 
DNA samples was limited.  Despite this limitation, TP53 
mutations could be analyzed in 8/42 cases from CK and 
non-HR-FISH subgroup and all of them were negative. 
In accordance, although it has been described that nearly 
20% of patients with TP53 abnormalities show mutations 
in absence of 17p deletion [14, 15], this percentage is much 
lower in general untreated CLL cohorts  (4.5%) [16]. In 
this regard, despite the limited availability of information 
regarding TP53 mutational status, only a minority of CK 
and non-HR-FISH patients could harbor TP53 mutations 
and therefore could be misclassified. So that, it could be 
assumed that other factors than abnormal TP53 function 
are underlying the global poor outcome observed in this 
subgroup. On the other hand, despite the detection of 
unmutated IGHV was significantly associated with shorter 
OS in the global cohort (55 mo vs 133 mo; P < 0.001), 
the limited availability of IGHV data did not allow the 
stratification by both IGHV and CK in the OS assessment. 
Mounting evidence suggests a relevant role 
of CBA in risk assessment of CLL patients. Indeed, 
Rigolin et al. demonstrated that 25-37% of patients 
showing no aberrations by FISH carried chromosomal 
abnormalities not covered by the standard FISH panel, 
which strongly correlated with worse prognosis [17]. 
Moreover, Jaglowski et al. described that both the number 
of karyotypic abnormalities as a continuous variable and 
the CK detection (defined as ≥ 5 abnormalities) could 
predict a worse clinical outcome in patients undergoing 
reduced-intensity conditioning allogeneic stem cell 
transplantation; remarkably, both variables retained their 
predictive prognostic value even within patients with 
HR-FISH [6]. In this regard, a recent study described the 
impact of CK as an independent unfavorable prognostic 
factor in a prospective trial using chlorambucil-based 
regimens in CLL patients with relevant comorbidity. In 
accordance to our results, an important proportion of 
patients with CK lacking TP53 abnormalities (73% cases 
with CK) showed a dismal survival, equivalent to those 
patients with sole TP53 lesions [11].  Novel evidences 
suggesting the value of CBA have arisen with the recent 
development of new treatment agents in CLL. Initially, 
Thompson et al. demonstrated that CK showed stronger 
impact on outcome than delTP53 in CLL patients treated 
with ibrutinib [10]. Furthermore, this negative impact 
on the outcome of ibrutinib-treated patients has been 
subsequently confirmed after a longer 5-year follow-
up [18], as well as in a large “real-world” multicentric 
analysis of patients treated with novel agents in CLL [19]. 
It is noteworthy that a lack of any adverse prognostic 
effect of CK on idelalisib-treated have been recently 
reported [20]. However, this finding should be confirmed 
in a larger cohort of CLL undergoing idelalisib-based 
regimens. All these findings point out CK as a potent 
prognostic factor in the new therapies era, especially 
considering that ibrutinib treatment increased survival in 
treatment-naïve older CLL patients without TP53 deletion 
irrespectively of other historical poor prognostic factors, 
such as delATM or unmutated IGHV [5]. Nevertheless, 
patients with CK are indeed a heterogeneous group: 
Figure 1: (A) Cumulative incidence of treatment (TFT) for the presence of CK and/or HR-FISH and (B) Kaplan–Meier plot for overall 
survival (OS) and the presence of CK and/or HR-FISH.
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Table 1: Baseline characteristics of patients with unfavourable cytogenetic markers (CK and/or 
HR-FISH) at diagnosis
Patients characteristics
CK and non-HR-
FISH 
(N = 42)
non-CK and HR-
FISH 
(N = 113)
CK and HR-FISH 
(N = 57) P-value
Median age at diagnosis (range) 73 (46–87) 67 (27–90) 69 (45–88) 0.322
Male 31 (73.9%) 78 (69.0%) 35 (61.4%) 0.284
Diagnosis
   MBL 10 (23.8%) 13 (11.5) 4 (7.0%) 0.039
   CLL 32 (76.2%) 100 (88.5%) 53 (93.0%)
Advanced Binet stage * 9/42 (21.4%) 33/109 (30.3%) 11/56 (19.6%) 0.262
Lymphadenopathy 16/42 (38.1%) 56/110 (50.1%) 28/55 (50.9%) 0.323
Splenomegaly 3/40 (7.5%) 15/109 (13.8%) 8/53 (15.1%) 0.512
Hepatomegaly 2/42 (4.8%) 11/112 (9.8%) 2/56 (3.6%) 0.266
Absolute white blood cell count (x109/L) 16 (6–164) 17 (4–168) 21 (5–89) 0.122
Absolut lymphocyte count (x109/L) 11 (2–105) 11 (1–155) 14 (2–82) 0.091
Hemoglobin (g/dL) 14 (9–17) 14 (6–18) 14 (8–17) 0.219
Platelets (x109/L) 190 (42–473) 191 (10–413) 173 (34–331) 0.470
Lactate dehydrogenase (IU/L) 332 (160–1279) 340 (139–1094) 383 (156–1082) 0.237
Beta-2 Microglobulin (mg/L) 2.4 (1.0–10.0) 2.2 (1.0–13.4) 2.6 (1.1–8.4) 0.305
ZAP-70 positive** 7/20 (35.0%) 17/62 (27.4%) 16/31 (51.6%) 0.071
CD38 positive* 11/31 (35.5%) 33/96 (34.4%) 14/42 (33.3%) 0.982
Unmutated IGHV 1/5 (20.0%) 2/2 (100%) 13/14 (92.9%) 0.003
FISH
   13q deletion 16/42 (38.1%) 54/110 (49.1%) 34/55 (61.8%) 0.064
   Trisomy 12 24/42 (57.1%) 15/109 (13.8%) 7/54 (13.02%) < 0.001
   11q deletion (ATM) – 68/113 (60.2%) 25/57 (43.9%) N.A.
   17p deletion (TP53) – 50/113 (44.2%) 40/57 (70.2%) N.A.
Values are given as median (range) or number (%). Hemoglobin is expressed as mean (range). N.A. Not applicable.
*Binet stage was not available in five patients (information regarding physical examination and/or analytical parameters not 
provided).
**Positivity was considered when ZAP-70 > 20% and CD38 > 30%.
Table 2: Univariate and multivariate analysis on median overall survival (OS)
Variable Univariate Multivariate
  Median OS in months (95% CI) P-value
Hazard ratio 
(95% CI) P-value
Complex karyotype (CK) Positive 79 (23–135) < 0.001 1.66 (1.06–2.59) 0.027
 Negative NR
 
ATM deletion Positive 87 (64–108) 0.003 1.51 (0.93–2.43) 0.093
 Negative NR
 
TP53 deletion Positive 56 (34–77) < 0.001 3.03 (1.93–4.77) < 0.001
 Negative 197 (107–287)    
NR: Not reached.
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patients harboring multiple trisomies, namely +12+18+19, 
and non-HR-FISH show a particularly benign clinical 
evolution [21]. Herein, we detected nine such cases 
presenting a better outcome compared with the remaining 
CK cases (data not shown). This observation suggests that 
criteria for CK definition in CLL should be revised; and 
that cytogenetic complexity defined by solely numerical 
aberrations should not be unquestionably considered 
as an unfavorable prognostic marker in this entity [21]. 
Even though previous publications evaluate cytogenetic 
complexity by the number of abnormalities detected by 
CBA, as well as the number or total size of altered regions 
by genomic microarrays, standard criteria focusing on 
both the number and the nature of the abnormalities are 
highly needed to provide a more accurate prognostic 
marker in CLL. 
In conclusion, we report the existence of a subgroup 
of CLL patients with CK lacking HR-FISH abnormalities 
(delATM/delTP53) that show an equivalent impaired 
clinical evolution as those with HR-FISH and non-CK. 
Despite CK group is globally associated with advanced 
disease and poor prognostic markers, genetic basis other 
than TP53/ATM dysfunction underlying the heterogeneity 
of CK remain to be elucidated. In order to better determine 
the patients’ prognosis according to genomic complexity 
detected by CBA, and make possible to select tailored 
therapies, further investigation in larger patient cohorts 
with CBA data is required.
MATERIALS AND METHODS
Patient selection
We selected 1045 CLL and monoclonal B-cell 
lymphocytosis (MBL) patients (821 and 224, respectively) 
with available simultaneous karyotype and FISH at 
diagnosis or prior to therapy from the CLL/MBL database 
of the Grupo Cooperativo Español de Citogenética 
Hematológica (GCECGH) and Grupo Español de 
Leucemia Linfática Crónica (GELLC). Of note, MBL 
individuals were also included, as MBL represents an 
initial phase in the disease evolution, some of them harbor 
poor prognosis cytogenetics and could evolve to CLL 
requiring treatment during follow-up. The median time 
from diagnosis to CBA was 0.5 months (range, 0-229). 
The study was approved by the ethical committee of 
Hospital del Mar, Barcelona (ref. 2016/6861/I). 
Clinical information collected at diagnosis included 
demographics (age and gender), Binet stage, physical 
examination, and analytical information regarding absolute 
white blood cell and lymphocyte counts, platelet count, 
hemoglobin level, as well as lactate dehydrogenase (LDH) 
and serum beta2-microglobulin (B2M) concentrations. 
When available, CD38 and ZAP-70 expression and 
mutational status of immunoglobulin heavy chain 
genes (IGHV) were also compiled. Evolutive data on 
treatment administration and last follow-up were recorded 
(Supplementary Table 1).  Treatment administration and 
response evaluation were performed according to current 
guidelines [22–24].  At the end of the study, 30.2% 
of patients had required therapy. The most frequently 
used therapies in first-line treatments are detailed in 
Supplementary Table 2. Of note, only four of the included 
patients received novel agents acting independently of 
TP53 pathway (ibrutinib) during follow-up. 
Chromosome banding analyses and fluorescence 
in situ hybridization 
Chromosome banding analyses were mainly 
assessed on peripheral blood samples (n = 881, 84%), 
whereas bone marrow and lymph node samples were only 
analyzed in 159 and five cases, respectively. Cell cultures 
were set for 72 hours with TPA (12-O-tetradecanoyl-
phorbol-13-acetate) according to standard procedures. A 
minimum of 20 metaphases were analyzed when possible. 
Karyotypes were described following the International 
System for Human Cytogenetic Nomenclature (2013) 
[25]. Only those abnormalities detected in at least two 
metaphases or those detected in a single metaphase but 
further confirmed by FISH or in a subsequent CBA were 
considered. CK was defined as the presence of three or 
more chromosomal abnormalities in a single clone. Data 
from routine FISH panel for TP53 (17p13), ATM (11q22), 
D13S319 (13q14) and chromosome 12 centromeric region 
were obtained simultaneously to CBA.
Statistical analysis
Firstly, patients were classified according to the 
presence of CK independently of FISH results (CK vs non-
CK). Discrete variables were compared between groups by 
Chi-square or Fisher exact tests, while Mann-Whitney test 
was used for continuous variables. Time to first treatment 
(TFT) was defined as time from sampling to start of 
treatment or last follow-up; overall survival (OS) was 
defined as time from sampling to death or last follow-up. 
Both TFT and OS were assessed using cumulative incidence 
and Kaplan–Meier plots, respectively and the effect of 
different covariates was evaluated using the Gray’s and log-
rank test, respectively. The maintenance of the independent 
predictive value on OS was assessed in multivariate analyses 
using Cox proportional hazards regression models. To further 
clarify the impact of high-risk FISH deletions (ATM and/or 
TP53, HR-FISH) in CK prognosis, a second classification 
including CK and HR-FISH was performed. TFT and OS 
from four groups were compared: (1) CK and HR-FISH; 
(2) CK and non-HR-FISH; (3) non-CK and HR-FISH; and 
(4) non-CK and non-HR-FISH. Statistical analyses were 
performed using SPSS v.22 software (SPSS Inc, Chicago, 
IL, USA) and R v.3.2.2. Results were considered statistically 
significant for P-values < 0.05.
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